Amgen Announces Romosozumab Phase 2 Data Published In NEJM Show Significant Increases In Bone Mineral Density

Amgen (NASDAQ: AMGN ) and UCB (OTC: UCBJF ) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment